PCN181 Real-World Evidence (RWE) in Reimbursement, Pricing, and Health Technology Assessment (HTA) in ASIA. How CAN Rwe Supplement Trial DATA in Oncology Indications in a Premarketing Setting?
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.272
https://www.valueinhealthjournal.com/article/S1098-3015(21)00489-7/fulltext
Title :
PCN181 Real-World Evidence (RWE) in Reimbursement, Pricing, and Health Technology Assessment (HTA) in ASIA. How CAN Rwe Supplement Trial DATA in Oncology Indications in a Premarketing Setting?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00489-7&doi=10.1016/j.jval.2021.04.272
First page :
Section Title :
Open access? :
No
Section Order :
10843